With a flurry of new drug applications filed or approved recently, some promising Boston area companies have been moving from research to commercialization and emerging as more formidable players on the local biotechnology scene.
Vertex Pharmaceuticals Inc., the fast-growing Cambridge company, is leading the way. In May it won Food and Drug Administration approval to market a new tablet to treat hepatitis C. And last week the company, which is building a new headquarters on the South Boston Waterfront, filed an application with the FDA for a cystic fibrosis drug.